Ciwon Immunotherapy

Wadatacce

• Takaitawa

Takaitawa

Immunotherapy magani ne na ciwon daji wanda ke taimakawa tsarin rigakafin ku yaƙar kansa. Yana da nau'in maganin ilmin halitta. Maganin ilimin halittu yana amfani da abubuwan da aka yi daga ƙwayoyin rai, ko sigar waɗannan abubuwa waɗanda aka yi a cikin dakin gwaje-gwaje.

Doctors ba su yi amfani da rigakafin rigakafi ba kamar yadda sauran cututtukan ciwon daji, kamar tiyata, chemotherapy, da radiation radiation. Amma suna amfani da rigakafin rigakafi don wasu nau'o'in cutar kansa, kuma masu bincike suna yin gwajin asibiti don ganin ko yana aiki ga wasu nau'ikan.

Lokacin da kake da ciwon daji, wasu ƙwayoyin jikinka zasu fara ninka ba tare da tsayawa ba. Sun yadu cikin kyallen takarda. Reasonaya daga cikin dalilan da yasa kwayoyin cutar kansar zasu iya ci gaba da girma da bazuwa shine cewa suna iya ɓoyewa daga tsarin garkuwar ku. Wasu rigakafin rigakafin rigakafi na iya "yiwa alama" akan ƙwayoyin cutar kansa. Wannan ya sauƙaƙa maka don garkuwar jikinka ta gano da lalata ƙwayoyin. Nau'in farfadowa ne da aka yi niyya, wanda ke amfani da kwayoyi ko wasu abubuwa waɗanda ke afkawa takamaiman ƙwayoyin cutar kansa tare da ƙananan lahani ga ƙwayoyin halitta. Sauran nau'ikan maganin rigakafi suna aiki ta hanyar haɓaka garkuwar ku don aiki mafi kyau game da cutar kansa.

Kuna iya samun rigakafin rigakafi ta hanyar jijiyoyi (ta hanyar IV), a cikin kwayoyi ko capsules, ko a cikin cream don fata. Don ciwon daji na mafitsara, suna iya sanya shi kai tsaye cikin mafitsara. Kuna iya samun magani kowace rana, mako, ko wata. Ana ba da wasu magungunan rigakafi a cikin hawan keke. Ya danganta da nau'in cutar kansa, yadda ci gabanta yake, nau'in rigakafin rigakafin cutar da kuke samu, da kuma yadda yake aiki.

Kuna iya samun sakamako masu illa. Illolin da suka fi yaduwa sune halayen fata a wurin allura, idan kun samo ta ta hanyar IV. Sauran illolin na iya haɗawa da alamomin mura, ko da wuya, mawuyacin tasiri.

NIH: Cibiyar Cancer ta Kasa

• Yakin Cutar Canji: Saka da Wajen Magungunan Immunotherapy